Why GLP-1 prices move: teaser rates, step-ups, and supply

The price you see on a GLP-1 provider's homepage is rarely the price you'll pay six months in. That's not always a scam — the market genuinely moves — but a lot of the movement is engineered, and once you can see the mechanics, the offers get much easier to read. This is the editorial backbone of the Dose Brief tracker: watching how these prices actually behave over time.

The teaser rate

The most common pricing move is the teaser: a low first-month price designed to win the sign-up. It works because the moment you're on the medication is the moment you're least likely to shop around. There's nothing illegal about an intro rate — but a headline number that only applies to month one tells you almost nothing about what the program costs to stay on. The first question to ask any provider is simple: what do I pay in month two, and every month after?

The step-up

Closely related is the step-up: pricing that rises after an introductory window, or as you titrate to a higher dose. Some step-ups are disclosed clearly; others are buried. A desk that charges more for a higher dose should say so up front, and a desk that resets your rate after three months should say that too. When we score price stability, a provider that holds one flat rate through dose changes ranks above one whose line drifts upward — that's the whole point of tracking prices over time rather than snapshotting them once.

The stacked fee

Watch for costs that live outside the medication price: a membership fee, a consultation charge, a coaching subscription you can't unbundle, or shipping that isn't included. The advertised number can look great while the all-in monthly cost tells a different story. When you compare two providers, compare the total you'll actually be charged, not the two homepage stickers.

Supply, the invisible hand

Underneath all of this sits supply. When a molecule is hard to get, prices firm up and discounts vanish; when supply loosens and new desks pile in, competition drives prices down — until a regulatory shift tightens things again. The GLP-1 market has been through exactly this cycle, tied closely to the FDA drug-shortage list and the rules around compounding during a shortage¹². If you want that story in full, read GLP-1 shortages and supply. The takeaway for pricing: a rock-bottom rate that depends on loose supply is not a rate you can count on.

How to read a price like a tracker

Put it together into a habit. Find the ongoing monthly price, not the intro price. Add in every fee. Ask what happens at a higher dose. And weigh the number against how stable it's likely to be — a slightly higher price that holds can beat a cheaper one that resets. On our board we tag each provider's price direction (stable, rising, or falling) for this reason; you can see it in the provider briefs, and stability is one of the six factors behind the Brief Score. All pricing figures we cite reflect each provider's published pricing at our last review (July 2026), not a fixed guarantee.

The bottom line

GLP-1 prices move because providers design them to and because supply forces them to. Neither is a reason to panic — it's a reason to read the fine print and favor desks that make their pricing boring and predictable. Start with the 5-minute provider checklist, and if a compounded price looks too good to be true, sanity-check the provider with is compounded semaglutide legit?. This is buyer's guidance, not medical advice.